[1] Chen W, Zheng R, Peter PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2] Chang JY, Liu H, Balter P, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage Ⅰ non-small cell lung cancer[J]. Radiat Oncol, 2012, 7: 152. DOI: 10.1186/1748-717X-7-152.
[3] Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 967-973. DOI: 10.1016/j.ijrobp.2010.12.039.
[4] Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage Ⅰ-Ⅱ nonsmallcell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis[J]. Ann Oncol, 2013, 24(6): 1543-1548. DOI: 10.1093/annonc/mdt026.
[5] Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors[J]. Radiother Oncol, 2012, 102(3): 383-387. DOI: 10.1016/j.radonc.2011.12.023.
[6] Rowe BP, Boffa DJ, Wilson LD, et al. Stereotactic body radiotherapy for central lung tumors[J]. J Thorac Oncol, 2012, 7(9): 1394-1399. DOI: 10.1097/JTO.0b013e3182614bf3.
[7] Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 919-923. DOI: 10.1016/j.ijrobp.2010.11.060.
[8] Barriger RB, Forquer JA, Brabham JG, et al. A dosevolume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): 457-462. DOI: 10.1016/j.ijrobp.2010.08.056.
[9] Bongers EM, Botticella A, Palma DA, et al. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs[J]. Radiother Oncol, 2013, 109(1): 95-99. DOI: 10.1016/j.radonc.2013.10.011.
[10] Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data metaanalysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450. DOI: 10.1016/j.ijrobp.2012.04.043.
[11] Jiang X, Li T, Liu Y, et al. Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT)[J]. Radiat Oncol, 2011, 6: 140-146. DOI: 10.1186/1748-717X-6-140.
[12] McGrath SD, Mathuszak MM, Yan D, et al. Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy: a dosimetric and treatment efficiency analysis[J]. Radiother Oncol, 2010, 95(2): 153-157. DOI: 10.1016/j.radonc.2009.12.039.
[13] Holt A, van VlietVroegindeweij C, Mans A, et al. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensitymodulated radiotherapy techniques[J]. Int J Radiat Oncol Biol Phys, 2011, 81(5): 1560-1567. DOI: 10.1016/j.ijrobp.2010.09.014.
[14] Rossi MM, Peulen HM, Belderbos JS, et al. Intrafraction motion in stereotactic body radiation therapy for non-small cell lung cancer: intensity modulated radiation therapy versus volumetric modulated arc therapy[J]. Int J Radiat Oncol Biol Phys, 2016, 95(2): 835-843. DOI: 10.1016/j.ijrobp.2016.01.060.
[15] Ding L, Lo YC, Kadish S, et al. Volume modulated arc therapy (VMAT) for pulmonary stereotactic body radiotherapy (SBRT) in patients with lesions in close approximation to the chest wall[J]. Front Oncol, 2013, 3: 12. DOI: 10.3389/fonc.2013.00012.
[16] Ong CL, Verbakel WF, Cuijpers JP, et al. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques[J]. Radiother Oncol, 2010, 97(3): 437-442. DOI: 10.1016/j.radonc.2010.09.027.
[17] Kannarunimit D, Descovich M, Garcia A, et al. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy[J]. Technol Cancer Res Treat, 2015, 14(1): 4960. DOI: 10.7785/tcrt.2012.500394.
[18] Chi A, Ma P, Fu G, et al. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy[J]. PLoS One, 2013, 8(4): e59729. DOI: 10.1371/journal.pone.0059729.
[19] Chen A, Lee N, Yang C, et al. Comparison of intensity-modulated radiotherapy using helical tomotherapy and segmental multileaf collimator-based techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225[J]. Technol Cancer Res Treat, 2010, 9(3): 291-298.
[20] Meng LL, Feng LC, Wang YL, et al. Dosimetric comparison between helical tomotherapy and intensity-modulated radiation therapy plans for nonsmall cell lung cancer[J]. Chin Med J (Engl), 2011, 124(11): 1667-1671.
[21] Kinhikar RA, Ghadi YG, Sahoo P, et al. Dosimetric comparison of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for lung stereotactic body radiotherapy[J]. J Med Phys, 2015, 40(4): 190-197. DOI: 10.4103/0971-6203.170792.
[22] Rao M, Yang W, Chen F, et al. Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy[J]. Med Phys, 2010, 37(3): 1350-1359.
[23] Xhaferllari I, El-Sherif O, Gaede S. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus Tomotherapy[J]. J Appl Clin Med Phys, 2016, 17(5): 6291.
[24] Weyh A, Konski A, Nalichowski A, et al. Lung SBRT: dosimetric and delivery comparison of RapidArc, Tomotherapy, and IMR[J]. J Appl Clin Med Phys, 2013, 14(4): 4065. DOI: 10.1120/jacmp.v14i4.4065. |